Alpha interferon: a look to the future.
The alpha-interferons have been explored in a wide variety of clinical applications in cancer. Significant activity has been demonstrated in AIDS-related Kaposi's sarcoma, ovarian carcinoma, bladder carcinoma, malignant glioma, non-Hodgkin's lymphoma, chronic granulocytic leukemia, the carcinoid syndrome and hairy cell leukemia. Although these leads are promising, the research has only just begun.
Bonnem
E M
EM
D000477:Alkylating Agents / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic; D003131:Combined Modality Therapy; D005260:Female; D005910:Glioma / Q000628:therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D009279:Naphthacenes / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000628:therapy; D011743:Pyrimidines / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000628:therapy; D001749:Urinary Bladder Neoplasms / Q000628:therapy; D014748:Vinca Alkaloids / Q000627:therapeutic use
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D007370:Interferon Type I; D009279:Naphthacenes; D011743:Pyrimidines; D014748:Vinca Alkaloids